Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports
Fasciitis with eosinophilia (FE) is a rare connective tissue disease. Due to its rarity, large-scale studies are lacking, which makes its treatment challenging. Systemic corticosteroids (SCSs) are the cornerstone of treatment; however, additional immunosuppressive drugs (ISDs) are frequently necessa...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SMC MEDIA SRL
2020-03-01
|
Series: | European Journal of Case Reports in Internal Medicine |
Subjects: | |
Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/1485 |
id |
doaj-fefb76cfaaa24715ae9c5843c94130cc |
---|---|
record_format |
Article |
spelling |
doaj-fefb76cfaaa24715ae9c5843c94130cc2020-11-25T03:10:21ZengSMC MEDIA SRLEuropean Journal of Case Reports in Internal Medicine2284-25942020-03-0110.12890/2020_0014851141Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case ReportsGuiomar Pinheiro0Ana Rita Costa1Ana Campar2Teresa Mendonça3Internal Medicine Department, Centro Hospitalar Universitário do Porto, Porto, PortugalInternal Medicine Department, Centro Hospitalar Universitário do Porto, Porto, PortugalDepartment of Clinical Immunology, Centro Hospitalar Universitário do Porto, Porto, PortugalInternal Medicine Department, Centro Hospitalar Universitário do Porto, Porto, PortugalFasciitis with eosinophilia (FE) is a rare connective tissue disease. Due to its rarity, large-scale studies are lacking, which makes its treatment challenging. Systemic corticosteroids (SCSs) are the cornerstone of treatment; however, additional immunosuppressive drugs (ISDs) are frequently necessary (usually methotrexate). We report 2 patients, for whom an SCS and methotrexate were not a viable long-term option. In the first case, we were unable to taper the SCS dose without symptom relapse, the patient showed only a partial response to methotrexate and presented side effects. The second case never fully responded to the SCS and methotrexate and demonstrated serious SCS adverse effects. Both patients were started on tocilizumab with extremely favourable results, making this drug a potential therapeutic weapon for these patients.https://www.ejcrim.com/index.php/EJCRIM/article/view/1485eosinophilic fasciitisshulman's diseasetolicizumab |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Guiomar Pinheiro Ana Rita Costa Ana Campar Teresa Mendonça |
spellingShingle |
Guiomar Pinheiro Ana Rita Costa Ana Campar Teresa Mendonça Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports European Journal of Case Reports in Internal Medicine eosinophilic fasciitis shulman's disease tolicizumab |
author_facet |
Guiomar Pinheiro Ana Rita Costa Ana Campar Teresa Mendonça |
author_sort |
Guiomar Pinheiro |
title |
Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports |
title_short |
Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports |
title_full |
Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports |
title_fullStr |
Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports |
title_full_unstemmed |
Effectiveness of Tocilizumab in the Treatment of Fasciitis with Eosinophilia: Two Case Reports |
title_sort |
effectiveness of tocilizumab in the treatment of fasciitis with eosinophilia: two case reports |
publisher |
SMC MEDIA SRL |
series |
European Journal of Case Reports in Internal Medicine |
issn |
2284-2594 |
publishDate |
2020-03-01 |
description |
Fasciitis with eosinophilia (FE) is a rare connective tissue disease. Due to its rarity, large-scale studies are lacking, which makes its treatment challenging. Systemic corticosteroids (SCSs) are the cornerstone of treatment; however, additional immunosuppressive drugs (ISDs) are frequently necessary (usually methotrexate). We report 2 patients, for whom an SCS and methotrexate were not a viable long-term option. In the first case, we were unable to taper the SCS dose without symptom relapse, the patient showed only a partial response to methotrexate and presented side effects. The second case never fully responded to the SCS and methotrexate and demonstrated serious SCS adverse effects. Both patients were started on tocilizumab with extremely favourable results, making this drug a potential therapeutic weapon for these patients. |
topic |
eosinophilic fasciitis shulman's disease tolicizumab |
url |
https://www.ejcrim.com/index.php/EJCRIM/article/view/1485 |
work_keys_str_mv |
AT guiomarpinheiro effectivenessoftocilizumabinthetreatmentoffasciitiswitheosinophiliatwocasereports AT anaritacosta effectivenessoftocilizumabinthetreatmentoffasciitiswitheosinophiliatwocasereports AT anacampar effectivenessoftocilizumabinthetreatmentoffasciitiswitheosinophiliatwocasereports AT teresamendonca effectivenessoftocilizumabinthetreatmentoffasciitiswitheosinophiliatwocasereports |
_version_ |
1724659117519273984 |